NEW YORK – Ideaya Biosciences on Thursday said it has expanded a clinical trial collaboration with Pfizer to study its PKC inhibitor IDE196 with Pfizer's cMET inhibitor crizotinib (Xalkori) in solid tumors characterized by GNAQ or GNA11 mutations, such as metastatic uveal melanoma, skin melanoma, lung cancer, and colorectal cancer.
When studying metastatic uveal melanoma samples, Ideaya identified cMET expression as a biomarker that may help identify which patients will benefit from IDE196. Additionally, the combination of IDE196 and crizotinib has demonstrated preclinical activity.
Earlier this year, Ideaya said it was working with Pfizer to study IDE196 in combination with MEK inhibitor binimetinib (Pfizer/Array Biopharma's Mektovi) for patients with GNAQ or GNA11 hotspot-mutated solid tumors. That study enrolled the first patient in June.
In a statement announcing its expanded collaboration with Pfizer, Ideaya said that it is expecting to enroll the first patient in the IDE196 and crizotinib study by year end or early 2021.
The companies will develop the combination treatment together and share clinical trial data within a recently established joint development committee. Ideaya is sponsoring the trial and Pfizer will supply crizotinib for the study.
If these studies succeed in late-stage trials, Pfizer and Ideaya will negotiate a regulatory submission strategy at that time.